B O O K - American College of Rheumatology

ACR Poster Session A
148
Halls B1 & B2
2010 Program Book
MONDAY, NOVEMBER 8, 2010
Antiphospholipid Syndrome
1. Acquired Resistance to Activated Protein C Is a Feature of Both
Systemic Lupus Erythematosus (SLE) and Antiphospholipid
Syndrome (APS) and Is More Marked in Patients with SLE
and APS. Denis Wahl 3 , Stéphane Zuily 4 , Agnès Brunette 2 ,
Marie Prestat-Tilly 4 , Véronique Regnault 2 , Jean Devignes 1 and
Thomas Lecompte 1 , 1 Biological Haematology Department,
Nancy University Hospital, Vandoeuvre les Nancy, France,
2
INSERM U961, Nancy Université, Vandoeuvre les Nancy,
France, 3 Vascular Medicine Unit, Vandoeuvre les Nancy, France,
4
Vascular Medicine Unit, Nancy University Hospital, Vandoeuvre
les Nancy, France.
2. AGTRL1 and PRKCH Are Genetic Risk Factors for
Antiphospholipid Syndrome. Hisako Nakagawa 1 , Tetsuya
Horita 2 , Toshio Odani 2 , Yuichiro Fujieda 2 , Masaru Kato 2 , Kotaro
Otomo 2 , Yasuko Nakagawa 2 , Shinsuke Yasuda 2 , Tatsuya Atumi 2
and Takao Koike 2 , 1 Department of Medicine II, Hokkaido
University Graduate School of Medicine, Sapporo, Hokkaido,
Japan, 2 Department of Medicine II, Hokkaido University
Graduate School of Medicine.
3. Anti-β2 Glycoprotein I Antibodies from Leprosy Patients Do
Not Show Thrombogenic Effects in an In Vivo Animal Model.
Ricardo Forastiero 2 , Marta Martinuzzo 2 , Mariano Vega-
Ostertag 2 , Gabriela de Larranaga 2 and Silvia S. Pierangeli 1 , 1 Univ
of TX Medical Branch, Galveston, TX, 2 Universidad Favaloro,
Buenos Aires, Argentina.
4. Antiphospholipid Antibodies in Children with Systemic
Lupus Erythematosus – 18 Years of Clinical Experience
from North India. Surjit Singh 2 , Jasmina Ahluwalia 1 , Shano
Naseem 3 , Deepti Suri 2 and Amit Rawat 2 , 1 Department of
Hematology, Post Graduate Institute of Medical Education
and Research, Chandigarh, India, 2 Division of Pediatric Allergy
and Immunology, Advanced Pediatrics Centre, Post Graduate
Institute of Medical Education and Research, Chandigarh, India,
3
Division of Pediatric Hematology, Advanced Pediatrics Centre,
Post Graduate Institute of Medical Education and Research,
Chandigarh, India.
5. Antiphospholipid Score (aPL-S): A Comprehensive Predictive
Marker of Developing Thrombosis in Autoimmune Diseases.
Kotaro Otomo 1 , Tatsuya Atsumi 2 , Yuichiro Fujieda 3 , Masaru
Kato 3 , Olga Amengual 3 , Tetsuya Horita 3 , Shinsuke Yasuda 3
and Takao Koike 3 , 1 Hokkaido Graduate School of Medicine,
Department of Medicine II, Sapporo, Hokkaido, Japan,
2
Hokkaido Graduate School of Medicine, Department of
Medicine II, Sapporo, Japan, 3 Hokkaido Graduate School of
Medicine, Department of Medicine II.
6. Antiphospholipid Syndrome (APS) Clinical Research Task Force
(CRTF) Report. Doruk Erkan 2 , Ronald Derksen 6 , Roger A. Levy 3 ,
Samuel Machin 5 , Thomas Ortel 1 , Silvia S. Pierangeli 4 , Robert A.
S. Roubey 7 , Michael D. Lockshin 2 and on Behalf of APS Clinical
Research Task Force, 1 Duke University Health System, Durham,
NC, 2 Hospital for Special Surgery, New York, New York, NY,
3
Univ Estado Do Rio de Janeiro, Rio de Janeiro, Brazil, 4 Univ of
TX Medical Branch, Galveston, TX, 5 University College London
Hospitals, London, UK, 6 University Medical Centre, Utrecht,
Netherlands, 7 University of North Carolina, Chapel Hill, NC.
7. Decreased Fibrin Clot Porosity in Patients with Antifosfolipid
Syndrome. Anna Vikerfors 2 , Aleksandra Antovic 1 , Elisabet
Svenungsson 2 , Katarina Bremme 3 and Margareta Holmström 4 ,
1
Department of Clinical Sciences, Karolinska Institutet/Danderyd
Hospital, Stockholm, Sweden, 2 Department of Medicine,
Rheumatology Unit, Karolinska Institutet/Karolinska University
Hospital, Stockholm, Sweden, 3 Department of Woman and
Child Health, Division of Obstetrics and Gynaecology, Karolinska
Institutet/Karolinska University Hospital, Stockholm, Sweden,
4
Hematology Division, Department of Medicine, Karolinska
Institutet/Karolinska University Hospital, Stockholm, Sweden.
8. Global Analyses of Antiphospholipid Antibodies That Impair
Antithrombin Inactivation of Procoagulant Factors. Meifang
Wu 2 , Jennifer M. Grossman 3 , John FitzGerald 2 , Bevra H. Hahn 4
and Pojen P. Chen 1 , 1 UCLA Schl of Medicine, Los Angeles, CA,
2
UCLA School of Medicine, 3 University of California Los Angeles,
Sherman Oaks, CA, 4 University of California Los Angeles School
of Medicine, Los Angeles, CA.
9. Influenza Vaccination Can Induce New Onset Anticardiolipins
but Not β2-Glycoprotein-I Antibodies among Patients with
Systemic Lupus Erythematosusβ. Evan Glenn Vista 3 , Sherry
R. Crowe 3 , Amy B. Dedeke 3 , Jourdan R. Anderson 2 , Linda F.
Thompson 3 , Gillian Air 4 and Judith A. James 1 , 1 Oklahoma Med
Research Foundation, Oklahoma City, OK, 2 Oklahoma Medical
Research Foundation, 3 Oklahoma Medical Research Foundation,
Oklahoma City, OK, 4 University of Oklahoma Health Science
Center, Oklahoma City, OK.
10. Platelet Activation and Paradoxical Inhibition of ADP
Induced Aggregation by Antiphospholipid Antibodies. Kenji
Oku 4 , Tatsuya Atsumi 2 , Olga Amengual 3 , Masahiro Ieko 1 , Shin
Furukawa 6 , Hirohiko Kitakawa 6 , Yuji Hori 6 , Kazuyoshi Nihei 6 ,
Yuuichiro Fujieda 3 , Kotaro Otomo 5 , Masaru Kato 3 , Tetsuya
Horita 3 , Shinsuke Yasuda 3 and Takao Koike 3 , 1 Health Sciences
University of Hokkaido, 2 Hokkaido University Graduate School
of Medicine Internal Medicine II, Sapporo, Japan, 3 Hokkaido
University Graduate School of Medicine Internal Medicine II,
4
Hokkaido University Graduate School of Medicine Internal
Medicine II, Kushiro Red Cross Hospital, Japan, 5 Hokkaido
UniversityGraduate School of Medicine Internal Medicine II,
6
Kushiro Red Cross Hospital.
11. Prevalence and Prognostic Significance of Thrombotic
Microangiopathy in Rheumatologic Patients: Clinical and
Immunological Associations. Spyros Aslanidis, Athina
Pyrpasopoulou, Stella Douma, Areti Triantafyllou, Michail
Doumas and Chrysanthos Zamboulis, 2nd Propedeutic Dept of
Internal Medicine, Hippokration Hospital, Thessaloniki, Greece.
12. Prevalence of Antibodies to Prothrombin (PT) and
Prothrombin/Phosphatidylserine (PS) in a Cohort of Lupus
Anticoagulant (LAC) Positive Samples. R. Aguilar-Valenzuela 2 , J.
Dlott 1 , U. Khan 2 , M. Belter 1 , E. Doan 2 , N. Gould 1 , A. Schleh 2 and
S. Pierangeli 2 , 1 Quest Diagnostics, Chantilly, VA, 2 Univ of TX Med
Branch, Galveston, TX.
13. The Influence of Thrombovascular Events on the Quality
of Life in APS and SLE Patients. Amaris K. Balitsky, Valentina
Peeva, Jiandong Su, Erik Yeo, Carol Landolt-Marticorena, Dafna
D. Gladman, Murray B. Urowitz and Paul R. Fortin, University
of Toronto Antiphospholipid Clinic, Division of Rheumatology,
Toronto Western Hospital.
14. Utility of Anti-Phosphatidylserine/Prothrombin and IgA
Antiphospholipid Assays in Antiphospholipid Syndrome.
Ehtisham Akhter 3 , Walter L. Binder 2 , Zakera Shums 2 and
Michelle A. Petri 1 , 1 Timonium, MD, 2 Inova Diagnostics Inc, San
Diego, CA, 3 Johns Hopkins University, Baltimore, MD.